Skip to main content

Table 5 Comparison of clinical characteristics at the index visit between those with and without incident dysglycaemia and incident metabolic syndrome at the outcome visit

From: Advanced glycation end-products and its soluble receptor are not independent predictors of incident dysglycaemia or metabolic syndrome in women with polycystic ovary syndrome: a prospective observational study

Parameter

Incident dysglycaemia^

Incident metabolic syndrome^

No

(n = 172)

Yes

(n = 19)

P value

No

(n = 160)

Yes

(n = 21)

P value

BMI (kg/m2)

22.4

(20.5–25.0)

25.7

(20.8–31.1)

0.005*

22.0

(20.1–23.4)

25.7

(22.7–28.8)

< 0.001*

Free androgen index

3.0

(1.8–5.0)

5.3

(1.8–6.5)

0.102

2.7

(1.7–4.3)

3.6

(1.7–10.5)

0.200

HOMA-IR

1.3 (0.9–1.9)

1.6 (1.1–2.1)

0.027*

1.2

(0.9–1.7)

1.6

(1.4–2.1)

0.005*

AGEs (µg/ml)

14.5

(10.2–18.7)

17.4

(11.8–21.2)

0.110

14.7

(10.2–19.4)

14.0

(10.6–16.1)

0.481

sRAGE (pg/ml)

629.2

(492.5–821.0)

581.1

(436.9–866.0)

0.656

661.2

(553.5–836.9)

494.1

(469.2–700.3)

0.008*

  1. ^Those with existing dysglycaemia (n = 41) or metabolic syndrome (n = 51) at the index visit were excluded from the respective analyses
  2. *Statistically significant (p < 0.05)